Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab Weight-Based Dosing Efficacy Trial
NCT06943534Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in food allergy, sponsored by Massachusetts General Hospital. Started Jul 2025; status: recruiting.
02
Drugs
omalizumab
03
Conditions
food allergy
Beyond the preview
Go deeper on NCT06943534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06943534.